Loading clinical trials...
Loading clinical trials...
An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With Imlifidase
Conditions
Interventions
Imlifidase
Locations
1
United States
NYU Langone Health Transplant Institute
New York, New York, United States
Start Date
December 16, 2022
Primary Completion Date
February 5, 2024
Completion Date
May 8, 2024
Last Updated
October 21, 2025
Lead Sponsor
Hansa Biopharma AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions